Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
-
- Health & Fitness
-
Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at http://HCPLive.com/Clinical/Endocrinology.
Please direct podcast-related inquiries to PCampbell@MJHLifesciences.com.
Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The Endocrine Outlook.
-
2024 ACP Type 2 Diabetes Recommendations
The American College of Physicians has released new recommendations in favor of SGLT2i and GLP-1 RA and against the use of DPP-4i as second-line therapies to metformin in adults with type 2 diabetes and inadequate glycemic control. Released on the first day of the ACP’s Internal Medicine Meeting 2024, the pair of recommendations reflect the findings from a systematic review and network meta-analysis and cost-effectiveness analysis assessing the value of these therapies as both monotherapies and in combination with metformin.
Attendees at this year’s meeting, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the ACP’s latest recommendations in a special ACP 2024 edition of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives.
Video Version: https://www.hcplive.com/view/diabetes-dialogue-2024-acp-type-2-diabetes-recommendations -
STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies
In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, tackle a pair of related topics: what the STEP HFpEF DM trial from ACC.24 means for the diabetes community and the need for fair and equitable allocation of incretin-based therapies in the face of ongoing drug shortages and overwhelming demand.
-
What to Know about Sequel Med Tech's twiist AID System, with Alan Lotvin, MD
The diabetes community welcomed an additional tool to the armamentarium with the US Food and Drug Administration’s clearance of the twiist automated insulin delivery (AID) system on March 18, 2024. Cleared for use in patients aged 6 years and older with type 1 diabetes, the twiist, which is marketed by Sequel Med Tech, is billed as the first drug delivery system that directly measures volume and flow of inulin delivered with every micro-dose.
In this episode, Alan Lotvin, MD, co-founder and CEO of Sequel Med Tech, offers hosts a deep dive into the latest AID to receive approval, including the pump’s patient-centric design, why they chose to leverage the Tidepool Loop algorithm, plans for device launch, and more.
Chapters
00:00 - Start
01:00 - Lotvin Introduction
03:25 - Differences from Current AIDs
08:15 - Compatible CGMs
10:25 - Plans for Launch
12:05 - Design Discussion
16:50 - iPhone vs Android Compatibility
19:50 - Clinical Trials
22:20 - Tidepool Loop Algorithm
27:45 - Accuracy of Current Pumps -
Hot Topics and Updates from ATTD 2024
In the third and final recap episode from the 17th annual International Conference on Advanced Technologies & Treatments for Diabetes, hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into a series of topics from the meeting, including GLP-1 receptor agonist use and CGM technology, updates in once-weekly insulins, the concept of continuous ketone monitoring, and application of artificial intelligence into care.
Video version: https://www.hcplive.com/view/diabetes-dialogue-hot-topics-and-updates-from-attd-2024 -
T1D Glycemic Improvement and CRISTAL at ATTD 2024
In this episode, hosts provide insight from automated insulin delivery updates from the 17th annual International Conference on Advanced Technologies & Treatments for Diabetes. The specific topics of note covered in this study include new data related to diabetes technology use from the Type 1 Diabetes (T1D) Exchange and a read-out of data from the CRISTAL trial.
-
FLOW Trial and Chronic Kidney Disease Updates, with Brendon Neuen, MBBS, PhD
In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives hosts are joined by Brendon Neuen, MBBS, PhD, nephrologist and director of the Kidney Trials Unit at Royal North Shore Hospital and senior research fellow at The George Institute for Global Health.
During the episode, Neuen talks about the FLOW trial, topline results, how the rapid advancement in pharmacotherapies has altered conversations around management, the concept of 4 pillars of GDMT for CKD in type 2 diabetes, and how to approach sequencing of these therapies.
Video Version: https://www.hcplive.com/view/diabetes-dialogue-flow-trial-and-chronic-kidney-disease-updates-with-brendon-neuen-mbbs-phd
Episode Highlights
00:32 - Neuen Introduction
01:55 - FLOW Trial
05:15 - Pillars of CKD Therapy
16:15 - Need for New Guidelines
21:15 - Barriers to Uptake
24:50 - Need for Screening
Customer Reviews
Excellent podcast!
Highly recommend for people living with diabetes! Thanks so much for the technology updates and diabetes management info you provide! :)